Testing Methods for Improving Emotional Salience of Risk Information: Results from a Decision Aid about Tamoxifen and Raloxifene

We have previously shown that when patients learn about the risks and benefits of tamoxifen, women at high risk of breast cancer are overwhelmingly not interested. In this study, we tested 5 additional factors for communicating the risks/benefits of tamoxifen (and now a second prevention drug, raloxifene). These factors also included manipulations that could affect the emotional salience of the risk/benefit message. In this talk, I will describe the factors studied and their impact on knowledge, risk perception, behavioral intentions, and actual behavior.

About the Speaker

Angela Fagerlin, PhD

Angela Fagerlin, PhD, is Co-Director of the Center for Bioethics and Social Sciences in Medicine and Professor of Medicine at the University of Michigan. Dr. Fagerlin is also a Research Scientist at the VA Ann Arbor Center for Clinical Management Research. Her primary research focuses are testing methods for communicating the risks and benefits of treatment to patients (e.g., in decision aids) and testing how patient decision aids can affect patient physician communication. Her other research includes studying cognitive biases involved in medical decision making and the use of living wills at the end of life.